Macky Natha

机构：Intercept Pharmaceuticals (United States)

发表论文 27 篇 · 总被引 373 次 · h-index 4

代表论文

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study (2021 · Journal of Hepatology · 被引 161)
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials (2016 · Clinical Infectious Diseases · 被引 101)
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials (2016 · Clinical Infectious Diseases · 被引 93)
Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis (2017 · Gastroenterology · 被引 6)
Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH (2018 · Gastroenterology · 被引 3)
Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH (2018 · Gastroenterology · 被引 1)